RxDoctor Payments DataLook up a doctor →

Charles Mouch, MD

Interventional Pain Medicine · San Marcos, TXNPI 1851740583

Payments from drug & device makers

$56,982in general payments, 2019–2025

Across 557 payments — averaging $102.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$28K
  • Medtronic$8K
  • Painteq LLC$4K
  • Globus Medical$3K
  • Spinal Simplicity, LLC$3K
  • Boston Scientific$3K
  • plus $7K from 20 others

What the payments were for

  • Consulting fees$9,00016%
  • Speaking & faculty fees$11,37520%
  • Grants$4,3758%
  • Travel & lodging$7,49213%
  • Food & beverage$22,68640%
  • Education$2,0544%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,982 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$414,270
Medicare patients
506
Services billed
30,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,596$41,428
BelbucaBuprenorphine Hcl33$26,587
Xtampza ErOxycodone Myristate31$15,225
Buprenorphine36$12,744
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen296$6,695
NucyntaTapentadol Hcl12$6,618
Fentanyl40$4,356
Pregabalin110$3,007
Lidocaine22$2,557
Morphine Sulfate ErMorphine Sulfate79$1,880
Oxycodone Hcl99$1,552
Gabapentin117$1,500
Acetaminophen-CodeineAcetaminophen With Codeine68$1,273
Tramadol Hcl ErTramadol Hcl16$1,135
Hydromorphone Hcl60$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$58$48,43076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →